Launch of new.co.uk Marketing Campaign

Medpal AI PLC

10 June 2026

 

10 June 2026

MedPal AI plc

("MedPal AI") or the "Company")

Commercial Update: new.co.uk Marketing Campaign Launch and Positioning Ahead of Anticipated UK Oral GLP-1 Availability

MedPal AI plc (AIM: MPAL; FRA: Z1N), the AI-native digital health and pharmacy group, is pleased to provide an update on the commercial development of its private weight management clinic, New Health, operating at new.co.uk.

Marketing campaign commenced

The Company has commenced a paid digital marketing campaign for new.co.uk across Meta and Google, supporting the build-out of New Health's GLP-1 weight management proposition. The campaign forms part of the previously announced marketing investment in the New Health platform and is designed to drive patient acquisition and brand awareness in the UK private weight management market.

Market context

The Directors believe the UK private GLP-1 weight management market continues to expand rapidly. On 7 June 2026, Novo Nordisk Inc. announced that prescriptions for the oral formulation of its semaglutide weight-loss product had surpassed three million in the United States since its launch there in January 2026, with the company reporting that more than 80% of new prescriptions were for patients new to GLP-1 therapy - indicating that oral GLP-1 therapy is expanding the treated population rather than displacing existing therapies.

An oral formulation of semaglutide for weight management is currently under review by the UK Medicines and Healthcare products Regulatory Agency (MHRA), with a regulatory decision anticipated in 2026.

Strategic positioning

MedPal operates NHS Distance Selling Pharmacy infrastructure with automated dispensing capacity across its Runcorn and Swaffham hubs. The Directors believe this dispensing infrastructure, combined with the New Health clinical platform, means that the Company is well positioned to participate in the UK oral GLP-1 weight management opportunity as and when such therapies receive UK marketing authorisation.

Jason Drummond, Founder and Chief Executive Officer of MedPal, commented:

"The scale of patient demand for GLP-1 therapy is one of the defining healthcare trends of this decade, and the data emerging from the US oral launch underlines how much of that demand is coming from people new to the treatment. We are investing now to build new.co.uk into a recognised UK brand in weight management, so that MedPal is well positioned to serve patients across both injectable and, in due course and subject to regulatory approval, oral therapies. Our pharmacy dispensing infrastructure is a genuine differentiator as this market matures."

Enquiries:

MedPal AI plc Jason Drummond, Chief Executive Officer	Via Square1 Consulting
Cairn Financial Advisers LLP        Louise O'Driscoll/Jo Turner	[phone]
Oak Securities (a trading name of Merlin Partners LLP) Tim Dainton/Calvin Man	[phone]
Clear Capital Markets Limited Bob Roberts	[phone]
Square1 Consulting David Bick	[phone] [phone]

About MedPal AI

MedPal AI is a UK-based digital health company building the MedPal Health OS - a vertically integrated, closed-loop platform spanning AI wellness, clinical services, and automated pharmacy fulfilment. Its core app aggregates data from over 100 wearable devices and health apps (including Apple Health, Fitbit, Garmin, and Whoop) into a unified health profile, offering personalised, non-clinical lifestyle guidance through its AI wellness coach and acting as the consumer front door to the Company's clinical and pharmacy services.

Through its wholly owned subsidiary MedPal Limited, the Company operates a 24/7 AI-powered automated pharmacy distribution centre, providing nationwide NHS and private prescription services. The facility leverages BD Rowa VMAX robotic dispensing technology integrated with AI triage to deliver rapid, cost-effective medication fulfilment with same-day and next-day delivery capabilities.

MedPal AI has a partnership agreement with Epassi UK Limited, which will, for a limited time, grant exclusive, zero-cost access to the MedPal AI app across Epassi's network of 11M+ employees at major firms. The Company's LEI is 984500EDP8B0A14CBA61.

Forward Looking Statements

This announcement contains forward-looking statements, which are based on the Company's current expectations, intentions and projections regarding its future performance, anticipated events or trends and other matters that are not historical facts. Forward-looking statements are often identified by words such as "believes", "expects", "intends", "may", "will", "should", "could", "plans", "targets", "aims" or similar expressions. Such statements are subject to risks, assumptions and uncertainties and actual results, performance or events may differ materially from those expressed or implied by them. The Company undertakes no obligation to update any forward-looking statements, except as required by applicable law, the AIM Rules for Companies, the UK Market Abuse Regulation or other applicable regulation.

 

END